11.08
+0.3(+2.78%)
Currency In USD
| Previous Close | 10.78 |
| Open | 10.73 |
| Day High | 11.12 |
| Day Low | 10.64 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 39,176 |
| Average Volume | 84,636 |
| Market Cap | 68.18M |
| PE | -0.82 |
| EPS | -13.54 |
| Moving Average 50 Days | 9.02 |
| Moving Average 200 Days | 8.56 |
| Change | 0.3 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $29.85 as of December 10, 2025 at a share price of $11.08. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $474.32 as of December 10, 2025 at a share price of $11.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodiumSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharm
Aligos Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, toda